Premium
Vimentin: an evaluation of its role as a tumour marker
Author(s) -
LEADER M.,
COLLINS M.,
PATEL J.,
HENRY K.
Publication year - 1987
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.1987.tb02609.x
Subject(s) - vimentin , pathology , cytokeratin , synovial sarcoma , monoclonal antibody , immunohistochemistry , sarcoma , mesenchymal stem cell , antibody , biology , medicine , immunology
In this study we examined 198 sarcomas, 38 carcinomas, 13 ‘tumours with a spindle cell component’and 22 malignant melanomas with a commercial monoclonal vimentin antibody. All histopathological material was formalin fixed and paraffin embedded. The results show this antibody to be a sensitive and specific marker of mesenchymal derivation or differentiation. It is a useful tool in separating sarcomas from most carcinomas, and in separating malignant melanomas from carcinomas. When used in combination with a cytokeratin antibody it identifies carcinosarcomas and synovial sarcomas.